ArticleBMC gastroenterology2025
Role of non-invasive serological and CT imaging parameters in assessing portal hypertensive gastropathy severity.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Advances in the diagnosis and treatment of portal hypertensive gastrointestinal and bile duct disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionTo compare serological and CT imaging parameters between the mild and severe portal hypertensive gastropathy (PHG) group, and find out the non-invasive predictive markers for PHG severity based on these differences.
methodsThree hundred one patients were enrolled in our retrospective study. The PHG severity was assessed by esophagogastroduodenoscopy (EGD), and serological markers were measured within 48 h before EGD, and CT scans were performed within one week after EGD. Differences in age, gender, etiology, serological and CT imaging parameters, and arterial-phase gastric wall enhancement in CT scans were analyzed between the mild and severe PHG groups.
resultsNo significant differences were observed in gender, age, etiology, serological markers, or MELD score between the two groups (all P > 0.05). However, spleen length, spleen volume, PLT/spleen length ratio, and PLT/spleen volume ratio differed significantly (P = 0.003, 0.011, 0.019, and 0.014, respectively). The optimal cutoff values for predicting PHG severity were 131.4 (AUC = 0.619), 613.29 (AUC = 0.596), 0.42 (AUC = 0.588), and 0.07 (AUC = 0.592), respectively. Patients with severe PHG demonstrated significantly greater arterial-phase gastric wall enhancement compared to mild PHG cases.
conclusionSpleen length, spleen volume, and the platelet-to-spleen ratios presented predictive value for PHG severity, albeit with limited discriminative ability. Additionally, moderate-to-severe arterial phase gastric wall enhancement in CT scans may serve as a potential indicator of severe PHG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.